KeywordsPlasmodium falciparum; circumsporozoite protein; CSP; monoclonal antibody; 2A10; 3C1; 3C2; 3D3; Fc engineering; silent effector function; IgG1; IgG2; IgG4; IgG sigma; developability; pharmacokinetics; crystal structure; upstream; downstream; host cell protein; CHO; ATPE; iCCC; dengue virus; NS1; Zika virus; mAbs; antibody recognition; amino acid sequences; multiple myeloma; monoclonal antibody; immunomodulatory activity; bone marrow microenvironment; IDH1; R132H; novel rabbit monoclonal antibody; B-cell cloning; immunohistochemistry; interfacial partitioning; cell harvest; capture; aqueous two-phase extraction; horizontal settler; static mixer; process integration; continuous phase separation; inline concentration measurements; UV/VIS spectral analysis; PAT for monoclonal antibodies; live pooling; peak deconvolution; antibody; antigen; small-angle scattering; docking; modeling; simulation; Monte Carlo; cell culture; glycosylation; media supplementation; MnCl2; controllability analysis; bispecific antibodies; CD47; antitumor immunity; immunotherapy; immunosurveillance; checkpoint inhibitors; phagocytosis; bacterial infections; monoclonal antibodies; pharmacokinetics; pharmacodynamics; CARPA; complement; complement activation; factor H; hypersensitivity; infusion reaction; monoclonal antibody therapy; pseudoallergic reaction; n/a
